The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients

Parkinsonism and Related Disorders

Volumn 4, Issue 2, 1998, Pages 61-63

  Jost, Wolfgang H ^a   Bellon, Anke K ^b   Kaiser, Thomas ^b   Schrank, Bertold ^a  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Blood pressure; Dopamine agonists; Parkinson's disease; Ropinirole

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ROPINIROLE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; STANDING;

EID: 0032144613     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(98)00014-5     Document Type: Article

References (14)

1. Bellon A.K., Jost W.H., Schimrigk K. Hormonelle Regulation beim Parkinson Syndrom. Dtsch Med Wschr. 121:1996;1077-1083.
2. 2 agonist. Pharmacol Biochem Behavior. 38:1991;147-154.
3. Rascol O., Brooks D.J., Brunt E.R., Korczyn A.D., Poewe W.H., Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord. 13:1998;39-45.
4. Benz P., Jost W.H. Neurodegenerative Prozesse: 'Diagnoserevolution' PET. Die Positronen-Emissions-Tomographie beim Parkinson Syndrom und bei Morbus Alzheimer. Z Allg Med. 73:1997;746-749.
5. Ewing D.J., Martyn C.N., Young R.J., Clarke B.F. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 8:1985;491-498.
6. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin. Autonomic Res. 1996;6:125-126.
7. Jost W.H., Bellon A.K., Schimrigk K. The impact of bromocriptine on blood pressure, heart rate, and noradrenaline concentration after active orthostasis in Parkinsonian patients. Parkinsonism Relat Disord. 3:1997;171-172.
8. Jost W.H., Autonome Regulationsstörungen beim Parkinson Syndrom. Homburg/Saar: Habilitationsschrift, 1995.
9. Durrieu G., Senard J.M., Tran M.A., Rascol A., Montastruc J.L. Effects of levodopa and bromocriptine on blood pressure and plasma catecholamins in Parkinsonians. Clin Neuropharmacol. 14:1991;84-90.
10. Poewe W, Benke T, Ransmeyr G. Kreislaufregulationsstörungen beim Parkinson-Syndrom - Beziehungen zu klinischen Subtypen der Erkrankung. In: Fischer PA, editor. Vegetativstörungen beim Parkinson-Syndrom, vol. 4. Frankfurter Parkinson-Symposium, 1984:333-344.
11. Quinn N., Illas A., Lhermitte F., Agid Y. Bromocriptine in Parkinson's disease: a study of cardiovascular effects. J Neurol Neurosurg Psychiat. 44:1981;426-429.
12. Ziegler M.G., Lake C.R., Williams A.C., Teychenne P.F., Shoulson I., Steinsland O. Bromocriptine inhibits norepinephrin release. Clin Pharmacol Ther. 25:1979;137-142.
13. Ziegler M.G., Kennedy B., Holland O.B., Murphy D., Lake C.R. The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems. Int J Clin Pharmacol Ther Toxicol. 23:1985;175-179.
14. Churchyard A., Mathias C.J., Boonkongchuen P., Lees A.J. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiat. 63:1997;228-234.